CTLA4 and non-small cell lung carcinoma: Studies investigating combinations of immunotherapies, such as checkpoint inhibitors like pembrolizumab and nivolumab, with other substances like CTLA-4 inhibitors, are demonstrating substantial promise in NSCLC.